XOMA Royalty (DB:X0M1) - Stock Price, News & Analysis

X0M1 Stock Overview

Operates as a biotech royalty aggregator in the United States and the Asia Pacific. More details

X0M1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 77.96% per year

Risk Analysis

Shareholders have been diluted in the past year

XOMA Royalty Corporation Competitors

Heidelberg Pharma

XTRA:HPHA

€103.9m

Formycon

XTRA:FYB

€827.2m

Biotest

XTRA:BIO3

€1.4b

Medigene

XTRA:MDG1

€22.6m

Price History & Performance

Summary of all time highs, changes and price drops for XOMA Royalty
Historical stock prices
Current Share Price	US$28.40
52 Week High	US$29.80
52 Week Low	US$13.40
Beta	0.90
11 Month Change	10.08%
3 Month Change	11.81%
1 Year Change	100.00%
33 Year Change	40.59%
5 Year Change	32.83%
Change since IPO	-71.31%

Recent updates

Shareholder Returns

	X0M1	DE Biotechs	DE Market
7D	2.9%	-0.7%	-0.02%
1Y	100.0%	-17.2%	8.2%

Return vs Industry: X0M1 exceeded the German Biotechs industry which returned -17.5% over the past year.

Return vs Market: X0M1 exceeded the German Market which returned 7.4% over the past year.

Price Volatility

Is X0M1's price volatile compared to industry and market?
X0M1 volatility
X0M1 Average Weekly Movement	6.2%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: X0M1 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: X0M1's weekly volatility has decreased from 14% to 6% over the past year.

About the Company

Founded	Employees	CEO	Website
1981	13	Owen Hughes	xoma.com

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

XOMA Royalty Corporation Fundamentals Summary

How do XOMA Royalty's earnings and revenue compare to its market cap?
X0M1 fundamental statistics
Market cap	€340.24m
Earnings (TTM)	-€34.03m
Revenue (TTM)	€20.75m

16.5x

P/S Ratio

-10.0x

P/E Ratio

Is X0M1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
X0M1 income statement (TTM)
Revenue	US$21.61m
Cost of Revenue	US$2.04m
Gross Profit	US$19.57m
Other Expenses	US$55.00m
Earnings	-US$35.43m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.01
Gross Margin	90.58%
Net Profit Margin	-164.00%
Debt/Equity Ratio	139.0%

How did X0M1 perform over the long term?

See historical performance and comparison

X0M1 Stock Overview

Rewards

Risk Analysis

XOMA Royalty Corporation Competitors

XTRA:HPHA

€103.9m

XTRA:FYB

€827.2m

XTRA:BIO3

€1.4b

XTRA:MDG1

€22.6m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: US$1.59 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

Recent updates

Third quarter 2024 earnings released: US$1.59 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.50 loss per share (vs US$0.69 profit in FY 2021)

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.51 loss in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.31 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

XOMA Corporation, Annual General Meeting, May 18, 2022

Now 22% undervalued

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

CEO & Director recently sold €254k worth of stock

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue beats expectations

New 90-day high: €29.32

XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

Revenue misses expectations

Third quarter 2020 earnings released: US$0.098 loss per share

New 90-day high: €20.84

XOMA Corporation Earns $25 Million Milestone Payment

XOMA Corporation announced that it has received $1.4 million in funding from Rezolute, Inc.

New 90-day high: €17.92

XOMA Corporation to Report Q2, 2020 Results on Aug 06, 2020

Earnings released

New 90-day low - €14.03

Shareholder Returns

Price Volatility

About the Company

XOMA Royalty Corporation Fundamentals Summary

16.5x

-10.0x